Hansa Biopharma AB
Clinical trials sponsored by Hansa Biopharma AB, explained in plain language.
A biopharmaceutical company developing immunomodulatory therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug could unlock kidney transplants for sensitized kids Results expected Feb 2027 (estimated)
-
New hope for rare kidney disease? trial tests imlifidase
Disease control Stopped earlyThis study tested a new drug called imlifidase for people with severe Goodpasture disease, a rare condition where the immune system attacks the kidneys and lungs. The trial compared imlifidase plus standard care to standard care alone in 50 adults with poor kidney function. The g…
Phase 3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo aims to stop immune attack after kidney transplant
Disease control Stopped earlyThis study tested whether a drug called imlifidase, given with other medications, could prevent the immune system from attacking a new kidney in highly sensitized patients. These patients have a very high risk of rejecting a donated kidney. The study was stopped early after only …
Phase 2 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC